Role of tumor necrosis factor-alpha inhibition with inflixiMAB in cancer therapy and hematopoietic stem cell transplantation. Review uri icon

Overview

abstract

  • Tumor necrosis factor (TNF)-alpha is a central cytotoxic and proinflammatory cytokine. Research on the benefits of TNF-alpha inhibition as a form of therapy has focused almost exclusively on autoimmune, inflammatory disorders. InflixiMAB, a chimeric antibody to human TNF-alpha, was recently approved for the management of Crohn disease and rheumatoid arthritis. The potential applications of inflixiMAB in the management of cancer are just beginning to be explored. This article reviews the biology, mechanism of action, pharmacology, and toxicity of inflixiMAB. Existing clinical experience and inflixiMAB's potential role as an immunosuppressant and antitumor agent in the management of cancer are also discussed.

publication date

  • November 1, 2000

Research

keywords

  • Antibodies, Monoclonal
  • Antirheumatic Agents
  • Hematopoietic Stem Cell Transplantation
  • Neoplasms
  • Tumor Necrosis Factor-alpha

Identity

Scopus Document Identifier

  • 0034514152

Digital Object Identifier (DOI)

  • 10.1097/00001622-200011000-00011

PubMed ID

  • 11085458

Additional Document Info

volume

  • 12

issue

  • 6